Cautionary Note Regarding Forward-Looking StatementsStatements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, our financial guidance for third-quarter and full-year 2011 (including, as applicable, estimated total net revenues, China-based Laboratory Services net revenues, U.S.-based Laboratory Services net revenue, Manufacturing Services net revenues, gross margins, operating margins, capital expenditures, effective tax rates, and other trends), planned investments in 2011 and beyond in new capabilities, facilities, senior personnel and capacity to promote and manage our growth and expanded offerings, an increased trend towards outsourced and offshored R&D and our related efforts to be the industry's alternative R&D engine to discover and develop new drugs for both the global and Chinese markets.
These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors, the state of the global economy may continue to be uncertain; pharmaceutical companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; the pressures being felt by our customers and pharmaceutical industry consolidation may adversely impact our business and the trends for outsource
|SOURCE WuXi PharmaTech (Cayman) Inc|
Copyright©2010 PR Newswire.
All rights reserved